Abstract:Background NF-κB is one of the key transcription factors in the inflammatory response, transactivates a series of pro-inflammatory genes and is therefore regarded as an important target for anti-inflammatory drug screening. Method We recombined the reporter gene vector with inserting the “neo” transcript into the vector pNF-κB-SEAP, made the reporter gene vector stable in a eukaryotic cell line. The recombinant reporter gene vector we named pNF-κB-SEAP-Neo was transfected into RAW264.7. We selected the transfected RAW264.7 cell line with G418 for 15 days and then get RAW264.7 cells stably expressing NF-κB-dependent SEAP named as RAW264.7-pNF-κB-SEAP cells. We treated the RAW264.7-pNF-κB-SEAP cells with NF-κB agonists as LPS, PolyI:C and TNF-α, NF-κB inhibitor as PDTC and BAY117085, in different concentrations and time points and tested the expression of the SEAP, constructed the drug screening system on the base of the RAW264.7-pNF-κB-SEAP cell line. 130 chemicals were screened with the drug screening system we constructed and one of these chemicals numbered w10 was found could inhibit the NF-κB significantly. At last, we verified the inhibition of w10 to expression of genes promoted with NF-κB in HepG2 and Hela, and to migration of Hela. Result In this study, we established a drug screening system based on RAW264.7 cells that stably expressed the NF-κB-dependent, SEAP reporter gene. To develop a standard method for drug screening using this reporter-gene cell line, the test approach of SEAP was optimized and basic conditions for drug screening were chosen. This included the initial cell number inoculated in a 96-well plate, the optimum agonist, inhibitor of NF-κB pathway and their concentrations during screening. Subsequently, 130 newly synthesized compounds were screened using the stable reporter-gene cell line. The anti-inflammatory effects of the candidate compounds obtained were further verified in 2 cancer cell lines. The results indicated that compound W10 (methyl 4-(4-(prop-2-yn-1-ylcarbamoyl) phenylcarbamoyl) benzoate) significantly inhibited SEAP production under the screening conditions. Further results confirmed that the precursor compound significantly inhibited the transcription of NF-κB target genes. Conclusion In conclusion, RAW264.7 cells, stably expressing the NF-κB-dependent SEAP-reporter gene, may provide a new, feasible, and efficient cellular drug-screening system.

[Establishment of a Cell Model Targeted to NFAT Signal Transduction Pathway for Preliminary Screening of FK506-like Immunosuppressants].

Establishment of A Cell Model Based on Fkbp12 Dimerization for Screening of Fk506-Like Neurotrophic Small Molecular Compounds

Establishment of A Cell Model Based on Fkbp12 Dimerization for Screening of Fk506-Like Small Molecular Compounds

[Establishment of High-Throughput Drug Screening Cell Models Based on JAK-STAT Signal Pathway].

Functional Identification of the Stable Transfection C5ar Cell Line Molt-4

NF45/NF90-mediated Rdna Transcription Provides a Novel Target for Immunosuppressant Development

[Application of NF-kappaB Reporter and Dual-Luciferase Assays in the Measure of Bioactivity of Interleukin-1Beta and Interleukin-1 Receptor Antagonist].

Model Based Targeting of Il-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the Jak Inhibitor Ruxolitinib

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

[Construction of Recombinant NF-κB Reporter Adenovirus and Activity Analysis].

Nk Cell-Based Approach for Screening Novel Functional Immune Genes

The "sneaking-ligand" approach: cell-type specific inhibition of the classical NF-κB pathway

Identification of Novel Nuclear Factor of Activated T Cell (NFAT)-associated Proteins in T Cells

Construction of Nuclear Factor-Kappa B Transgenic Cell Models

A Reporter Gene Assay for Determining the Biological Activity of Therapeutic Antibodies Targeting TIGIT

The Technical System Establishment of NF-KB Signaling Screen by HCS

Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs

High-throughput screening and in vitro evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-talk

Therapeutic Effects of FK506 on IgA Nephropathy Rat

The Biological Activities of a Novel Immunosuppressive Agent FK520

Identification and application of anti-inflammatory compounds screening system based on RAW264.7 cells stably expressing NF-κB-dependent SEAP reporter gene